IL109639A - High-concentration pharmaceutical preparations and methods for their preparation - Google Patents

High-concentration pharmaceutical preparations and methods for their preparation

Info

Publication number
IL109639A
IL109639A IL109639A IL10963994A IL109639A IL 109639 A IL109639 A IL 109639A IL 109639 A IL109639 A IL 109639A IL 10963994 A IL10963994 A IL 10963994A IL 109639 A IL109639 A IL 109639A
Authority
IL
Israel
Prior art keywords
mycophenolate mofetil
active agent
temperature
pharmaceutical formulation
liquefied
Prior art date
Application number
IL109639A
Other languages
English (en)
Hebrew (he)
Other versions
IL109639A0 (en
Inventor
Glenn Jay Samuels
Jung-Chung Lee
Charles Lee
Stephen Berry
Paul Joseph Jarosz
Original Assignee
Syntex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex Inc filed Critical Syntex Inc
Publication of IL109639A0 publication Critical patent/IL109639A0/xx
Publication of IL109639A publication Critical patent/IL109639A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL109639A 1993-05-13 1994-05-12 High-concentration pharmaceutical preparations and methods for their preparation IL109639A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/061,656 US5455045A (en) 1993-05-13 1993-05-13 High dose formulations

Publications (2)

Publication Number Publication Date
IL109639A0 IL109639A0 (en) 1994-08-26
IL109639A true IL109639A (en) 1998-02-08

Family

ID=22037233

Family Applications (1)

Application Number Title Priority Date Filing Date
IL109639A IL109639A (en) 1993-05-13 1994-05-12 High-concentration pharmaceutical preparations and methods for their preparation

Country Status (23)

Country Link
US (3) US5455045A (fi)
EP (1) EP0697866B1 (fi)
JP (1) JP3584037B2 (fi)
KR (1) KR100296214B1 (fi)
CN (1) CN1045884C (fi)
AT (1) ATE187067T1 (fi)
AU (1) AU674960B2 (fi)
BR (2) BR9406604A (fi)
CZ (1) CZ285297B6 (fi)
DE (1) DE69421918T2 (fi)
DK (1) DK0697866T3 (fi)
ES (1) ES2138661T3 (fi)
FI (1) FI114286B (fi)
GR (1) GR3032021T3 (fi)
HU (2) HU226470B1 (fi)
IL (1) IL109639A (fi)
NO (1) NO308828B1 (fi)
NZ (1) NZ266683A (fi)
PL (1) PL175583B1 (fi)
PT (1) PT697866E (fi)
RU (1) RU2135182C1 (fi)
TW (1) TW434010B (fi)
WO (1) WO1994026266A1 (fi)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2063791C (en) * 1989-08-17 2000-12-19 Michael John Story Hard gelatine capsule containing fat-soluble nutrients.
US5455045A (en) * 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
CA2216934A1 (en) * 1995-04-03 1996-10-10 Abbott Laboratories Homogeneous mixtures of low temperature-melting drugs and additives for controlled release
ID18663A (id) 1996-04-12 1998-04-30 Novartis Ag Komposisi farmasi berlapis enterik
UA72207C2 (uk) * 1998-04-07 2005-02-15 Брістол- Майєрс Сквібб Фарма Компані Фармацевтична композиція ефавіренцу з добавкою дезінтегруючих агентів у вигляді швидкорозчинних капсул або таблеток та спосіб її виготовлення
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
US6479496B1 (en) * 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
AU778203B2 (en) 2000-02-18 2004-11-25 Gilead Sciences, Inc. Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure
US6451798B2 (en) 2000-02-22 2002-09-17 Cv Therapeutics, Inc. Substituted alkyl piperazine derivatives
US6552023B2 (en) 2000-02-22 2003-04-22 Cv Therapeutics, Inc. Aralkyl substituted piperazine compounds
AU2001238590A1 (en) 2000-02-22 2001-09-03 Cv Therapeutics, Inc. Substituted piperazine compounds
AU2001239827A1 (en) 2000-02-22 2001-09-03 Cv Therapeutics, Inc. Substituted alkylene diamine compounds
US6677336B2 (en) 2000-02-22 2004-01-13 Cv Therapeutics, Inc. Substituted piperazine compounds
US6573264B1 (en) * 2000-10-23 2003-06-03 Cv Therapeutics, Inc. Heteroaryl alkyl piperazine derivatives
GB0124953D0 (en) * 2001-10-17 2001-12-05 Novartis Ag Organic Compounds
BR0311161A (pt) * 2002-05-21 2005-03-29 Cv Therapeutics Inc Método de tratamento de diabetes
US8822473B2 (en) * 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
JP2006510670A (ja) * 2002-12-05 2006-03-30 シーブイ・セラピューティクス・インコーポレイテッド 置換ヘテロ環化合物
DE60329323D1 (de) * 2003-01-03 2009-10-29 Cv Therapeutics Inc Substituierte heterozyklische verbindungen
AU2004209522A1 (en) * 2003-01-17 2004-08-19 Gilead Palo Alto, Inc. Substituted heterocyclic compounds useful in the treatment of cardiovascular diseases
GB0307553D0 (en) * 2003-04-01 2003-05-07 Novartis Ag Organic compounds
US20050187170A1 (en) * 2003-06-16 2005-08-25 Biocryst Pharmaceuticals, Inc. Enhancing the efficiency of RNA polymerase inhibitors by using inosine monophosphate dehydrogenase inhibitors
NZ544449A (en) * 2003-06-23 2008-10-31 Cv Therapeutics Inc Urea derivatives of piperazines and piperidines as fatty acid oxidation inhibitors
CA2550257A1 (en) 2003-12-18 2005-07-07 Cv Therapeutics, Inc. 1-akan-2-ol substituted piperazine and piperidine compounds
US7683188B2 (en) * 2004-04-26 2010-03-23 TEVA Gyógyszergyár Zártkōrūen Mūkōdō Részvénytársaság Process for preparation of mycophenolic acid and ester derivatives thereof
US20050250773A1 (en) * 2004-04-27 2005-11-10 Sandor Molnar Process for preparation of mycophenolate mofetil and other esters of mycophenolic acid
EP1768662A2 (en) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
US7439373B2 (en) * 2004-07-20 2008-10-21 TEVA Gyógyszergyár Zártkörúen Múködö Részvénytársaság Crystalline mycophenolate sodium
US7271169B2 (en) * 2004-09-08 2007-09-18 Cv Therapeutics, Inc. Substituted heterocyclic compounds
JP2008526879A (ja) * 2005-01-06 2008-07-24 シーブイ・セラピューティクス・インコーポレイテッド ラノラジンを含有する徐放性薬学的処方物
CN100393312C (zh) * 2005-04-18 2008-06-11 吴建梅 霉酚酸或其类似物的软胶囊及其制备方法
US20080281111A1 (en) * 2005-04-26 2008-11-13 Sandor Molnar Process for preparation of mycophenolate mofetil and other esters of mycophenolic acid
US8277839B2 (en) * 2006-07-06 2012-10-02 Ares Trading S.A. Oral pharmaceutical composition of anilinopyrimidine, preparation and use thereof
EP2051583A4 (en) * 2006-08-16 2011-09-14 Aspreva Pharmaceuticals Ltd COMPOSITIONS AND METHODS FOR TREATING VASCULAR, AUTOIMMUNE AND INFLAMMATORY DISEASES
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
CA2678272A1 (en) * 2007-02-13 2008-10-02 Cv Therapeutics, Inc. Use of ranolazine for the treatment of cardiovascular diseases
WO2008101012A1 (en) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Use of ranolazine for the treatment of non-coronary microvascular diseases
CA2678319A1 (en) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Use of ranolazine for the treatment of coronary microvascular diseases
WO2008116083A1 (en) * 2007-03-22 2008-09-25 Cv Therapeutics, Inc. Use of ranolazine for elevated brain-type natriuretic peptide
US20080299195A1 (en) * 2007-05-31 2008-12-04 Brent Blackburn Use of ranolazine for elevated brain-type natriuretic peptide
US20090076000A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched mycophenolate mofetil
AR068745A1 (es) * 2007-10-08 2009-12-02 Panacea Biotec Ltd Una composicion en forma de dosificacion farmaceutica oral de unidad de alta dosis de micofenolato sodico, metodo para utilizar dicha composicion y sus usos
EP2252294A1 (en) * 2008-02-06 2010-11-24 Gilead Sciences, Inc. Use of ranolazine for treating pain
WO2010004435A2 (en) * 2008-07-09 2010-01-14 Aspreva International Ltd. Formulations for treating eye disorders
EP2326717A4 (en) * 2008-08-26 2011-12-28 Intelligentnano Inc ON THE BASIS OF ULTRASONIC REINFORCED GROWTH OF MICROORGANISMS
US9012192B2 (en) * 2008-08-26 2015-04-21 Intelligentnano Inc. Ultrasound enhanced growth of microorganisms
US8962290B2 (en) 2008-08-26 2015-02-24 Intelligentnano Inc. Enhanced animal cell growth using ultrasound
EP2429526A1 (en) * 2009-05-14 2012-03-21 Gilead Sciences, Inc. Ranolazine for the treatment of cns disorders
ES2615511T3 (es) * 2009-05-19 2017-06-07 Celgene Corporation Formulaciones de 4-amino-2-(2,6-dioxopiperidina-3-il)isoindolin-1,3-diona
US8901128B2 (en) 2009-05-28 2014-12-02 Lupin Limited Pharmaceutical compositions of ranolazine
BR112012006433A2 (pt) 2009-09-25 2016-04-19 Lupin Ltd composição de libertação sustentada de ranolazina
TWI508726B (zh) 2009-12-21 2015-11-21 Gilead Sciences Inc 治療心房纖維性顫動之方法
TW201215392A (en) 2010-06-16 2012-04-16 Gilead Sciences Inc Use of ranolazine for treating pulmonary hypertension
WO2022063266A1 (zh) 2020-09-27 2022-03-31 中国石油化工股份有限公司 歧化与烷基转移催化剂及其制备和应用
CN114456835B (zh) 2020-10-22 2023-06-06 中国石油化工股份有限公司 一种汽油组分的处理系统和处理方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3374146A (en) * 1966-04-18 1968-03-19 American Cyanamid Co Sustained release encapsulation
US3705946A (en) * 1971-05-25 1972-12-12 Lilly Co Eli Method of treating hyperuricemia
JPS5542995B2 (fi) * 1972-02-24 1980-11-04
US3880995A (en) * 1973-05-14 1975-04-29 Lilly Co Eli Treatment of arthritis with mycophenolic acid and derivatives
US3903071A (en) * 1973-05-22 1975-09-02 Lilly Co Eli Mycophenolic acid derivatives
US4002718A (en) * 1974-10-16 1977-01-11 Arnar-Stone Laboratories, Inc. Gelatin-encapsulated digoxin solutions and method of preparing the same
US4145918A (en) * 1976-09-07 1979-03-27 Akzona Incorporated Freeze-thaw indicator
GB1572226A (en) * 1977-11-03 1980-07-30 Hoechst Uk Ltd Pharmaceutical preparations in solid unit dosage form
CA1125698A (en) * 1978-03-09 1982-06-15 Masaru Yoshida Process for preparing a polymer composition
US4567264A (en) * 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
DK164642C (da) * 1984-08-30 1992-12-14 Merrell Dow Pharma Farmaceutisk middel indeholdende terfenadin i form af en varmsmelte paafyldt paa kapsler
DE3438830A1 (de) * 1984-10-23 1986-04-30 Rentschler Arzneimittel Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung
US4820523A (en) * 1986-04-15 1989-04-11 Warner-Lambert Company Pharmaceutical composition
DE3613799C1 (de) * 1986-04-24 1987-09-03 Nattermann A & Cie Verwendung von Glycofurol zum Verfluessigen von Arzneimittelzubereitungen fuer das Abfuellen in Weichgelatinekapseln
US4727069A (en) * 1987-01-30 1988-02-23 Syntex (U.S.A.) Inc. Heterocyclic aminoalkyl esters of mycophenolic acid, derivatives thereof and pharmaceutical compositions
US4753935A (en) * 1987-01-30 1988-06-28 Syntex (U.S.A.) Inc. Morpholinoethylesters of mycophenolic acid and pharmaceutical compositions
US5175000A (en) * 1987-06-30 1992-12-29 Vipont Pharmaceutical, Inc. Free amine benzophenanthridine alkaloid compositions
US4936074A (en) * 1988-11-17 1990-06-26 D. M. Graham Laboratories, Inc. Process for preparing solid encapsulated medicament
WO1990011761A1 (en) * 1989-03-31 1990-10-18 The Children's Medical Center Corporation Treatment of aids dementia, myelopathy and blindness
US5368861A (en) * 1989-10-26 1994-11-29 Nippon Shinyaku Co., Ltd. Gastric preparation with sustained release
FR2657257B1 (fr) * 1990-01-19 1994-09-02 Rhone Poulenc Sante Procede de preparation de medicaments sous forme de perles.
DE69129459T2 (de) * 1990-08-10 1998-10-15 Anormed Inc Immunosuppressive zusammensetzungen
US5247083A (en) * 1992-07-10 1993-09-21 Syntex (U.S.A.) Inc. Direct esterification of mycophenolic acid
US5455045A (en) * 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
US5380879A (en) * 1994-02-18 1995-01-10 Syntex (U.S.A.) Inc. Derivatives of mycophenolic acid
US5467037A (en) * 1994-11-21 1995-11-14 International Business Machines Corporation Reset generation circuit to reset self resetting CMOS circuits

Also Published As

Publication number Publication date
NZ266683A (en) 1996-08-27
FI114286B (fi) 2004-09-30
PL311654A1 (en) 1996-03-04
DK0697866T3 (da) 2000-04-17
US5472707A (en) 1995-12-05
JP3584037B2 (ja) 2004-11-04
DE69421918T2 (de) 2000-03-30
BR1100723A (pt) 2000-04-18
NO954546D0 (no) 1995-11-10
CN1122571A (zh) 1996-05-15
AU6830194A (en) 1994-12-12
GR3032021T3 (en) 2000-03-31
HUT72978A (en) 1996-06-28
IL109639A0 (en) 1994-08-26
TW434010B (en) 2001-05-16
HU9503224D0 (en) 1996-01-29
FI955439A (fi) 1995-11-10
US5554384A (en) 1996-09-10
NO954546L (no) 1995-11-10
ATE187067T1 (de) 1999-12-15
FI955439A0 (fi) 1995-11-10
NO308828B1 (no) 2000-11-06
CZ295495A3 (en) 1996-02-14
HU226470B1 (en) 2008-12-29
CN1045884C (zh) 1999-10-27
PL175583B1 (pl) 1999-01-29
US5455045A (en) 1995-10-03
DE69421918D1 (de) 2000-01-05
PT697866E (pt) 2000-04-28
KR960702304A (ko) 1996-04-27
CZ285297B6 (cs) 1999-06-16
RU2135182C1 (ru) 1999-08-27
WO1994026266A1 (en) 1994-11-24
HU211270A9 (en) 1995-11-28
AU674960B2 (en) 1997-01-16
KR100296214B1 (ko) 2001-10-24
EP0697866B1 (en) 1999-12-01
ES2138661T3 (es) 2000-01-16
BR9406604A (pt) 1996-01-02
EP0697866A1 (en) 1996-02-28
JPH08510254A (ja) 1996-10-29

Similar Documents

Publication Publication Date Title
EP0697866B1 (en) High dose formulations
EP0097523B1 (en) Extended action controlled release compositions
RU2157203C2 (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования эндометриоза
EP0801562A1 (en) Pharmaceutical composition containing fenofibrate and polyglycolized glycerides
US3459850A (en) Sustained-release tablets,a process and a composition for their preparation
US20080026050A1 (en) Solid dose formulations of a thrombin receptor antagonist
DK159590B (da) Fremgangsmaade til forhindring af nedbrydning af thieno-pyridinderivater
US8901128B2 (en) Pharmaceutical compositions of ranolazine
US5693669A (en) Tilidine dihydrogen orthophosphate, method of preparing it and pharmaceutical preparation containing it
CA2162670C (en) High dose formulations of mycophenolate mofetil, mycophenolic acid and ranolazine
JP2002520285A (ja) ８−クロロ−６，１１−ジヒドロ−１１−（４−ピペリジリデン）−５Ｈ−ベンゾ［５，６］シクロヘプタ［１，２−ｂ］ピリジンの経口用組成物
EP0684042B1 (en) Oral solid pharmaceutical compositions containing as active ingredient gemfibrozil and process for preparing them
AU2004285316A1 (en) Pharmaceutical compositions based on idazoxan salt or one of the polymorphs thereof
US4105796A (en) Pharmaceutical compositions containing racemic or optically active 1-(2,6-dimethyl-phenoxy)-2-methylamino-propane and method of use
CN107007559B (zh) 一种稳定的口服药物组合物及其制备方法
CN115429797A (zh) 一种含氧氯吡格雷或其盐的组合物及其制备
CN112741827A (zh) 氨己烯酸固体制剂及其制备方法
SK284769B6 (sk) Farmaceutické formulácie obsahujúce pentaerytrityltetranitrát alebo jeho metabolity a spôsob jeho prípravy
CZ20002675A3 (cs) Tiagabinové prostředky s prodlouženým uvolňováním se sníženými vedlejšími účinky

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired